"Cage vs Age": Development of an innovative nanotechnology to halt the spread of abnormal Tau protein in Alzheimer's Disease
Project Member(s): Care, A.
Funding or Partner Organisation: National Foundation for Medical Research and Innovation
National Foundation for Medical Research and Innovation
Start year: 2021
Summary: Current medications prescribed for Alzheimer's Disease (AD) alleviate the symptoms of the disease but do not alter the brain mechanisms underpinning it. Hence, a disease modifying treatment for AD remains a major unmet clinical need. Our first-of-its-kind approach, using a novel nanocage platform of our own design, represents a significant disruption in the AD therapeutic space, and is aimed at targeting and preventing the pathological spread of tau in the disease.
FOR Codes: Neurodegenerative Disorders Related to Ageing, Nanomedicine, Synthetic Biology, Neurosciences, Clinical health